Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

Pharming Group N.V. announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome (APDS). Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗